CA 15-3: uses and limitation as a biomarker for breast cancer.

Hdl Handle:
http://hdl.handle.net/10147/207692
Title:
CA 15-3: uses and limitation as a biomarker for breast cancer.
Authors:
Duffy, Michael J; Evoy, Denis; McDermott, Enda W
Affiliation:
Department of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin 4, Ireland. Michael.J.Duffy@ucd.ie
Citation:
Clin Chim Acta. 2010 Dec 14;411(23-24):1869-74. Epub 2010 Sep 8.
Journal:
Clinica chimica acta; international journal of clinical chemistry
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207692
DOI:
10.1016/j.cca.2010.08.039
PubMed ID:
20816948
Abstract:
CA 15-3 which detects soluble forms of MUC-1 protein is the most widely used serum marker in patients with breast cancer. Its main use is for monitoring therapy in patients with metastatic disease. In monitoring therapy in this setting, CA 15-3 should not be used alone but measured in conjunction with diagnostic imaging, clinical history and physical examination. CA 15-3 is particularly valuable for treatment monitoring in patients that have disease that cannot be evaluated using existing radiological procedures. CA 15-3 may also be used in the postoperative surveillance of asymptomatic women who have undergone surgery for invasive breast cancer. In this setting, serial determination can provide median lead-times of 5-6 months in the early detection of recurrent/metastatic breast cancer. It is unclear however, whether administering systemic therapy based on this lead-time improves patient outcome. Consequently, expert panels disagree on the utility of regularly measuring CA 15-3 in the postoperative surveillance of asymptomatic women following a diagnosis of breast cancer. The main limitation of CA 15-3 as a marker for breast cancer is that serum levels are rarely increased in patients with early or localized disease.
Language:
eng
MeSH:
Animals; Breast Neoplasms/blood/*metabolism/pathology/surgery; Humans; Mucin-1/blood/chemistry/*metabolism; Neoplasm Metastasis; Postoperative Period; Preoperative Period; Tumor Markers, Biological/blood/chemistry/*metabolism
ISSN:
1873-3492 (Electronic); 0009-8981 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael Jen_GB
dc.contributor.authorEvoy, Denisen_GB
dc.contributor.authorMcDermott, Enda Wen_GB
dc.date.accessioned2012-02-01T10:35:06Z-
dc.date.available2012-02-01T10:35:06Z-
dc.date.issued2012-02-01T10:35:06Z-
dc.identifier.citationClin Chim Acta. 2010 Dec 14;411(23-24):1869-74. Epub 2010 Sep 8.en_GB
dc.identifier.issn1873-3492 (Electronic)en_GB
dc.identifier.issn0009-8981 (Linking)en_GB
dc.identifier.pmid20816948en_GB
dc.identifier.doi10.1016/j.cca.2010.08.039en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207692-
dc.description.abstractCA 15-3 which detects soluble forms of MUC-1 protein is the most widely used serum marker in patients with breast cancer. Its main use is for monitoring therapy in patients with metastatic disease. In monitoring therapy in this setting, CA 15-3 should not be used alone but measured in conjunction with diagnostic imaging, clinical history and physical examination. CA 15-3 is particularly valuable for treatment monitoring in patients that have disease that cannot be evaluated using existing radiological procedures. CA 15-3 may also be used in the postoperative surveillance of asymptomatic women who have undergone surgery for invasive breast cancer. In this setting, serial determination can provide median lead-times of 5-6 months in the early detection of recurrent/metastatic breast cancer. It is unclear however, whether administering systemic therapy based on this lead-time improves patient outcome. Consequently, expert panels disagree on the utility of regularly measuring CA 15-3 in the postoperative surveillance of asymptomatic women following a diagnosis of breast cancer. The main limitation of CA 15-3 as a marker for breast cancer is that serum levels are rarely increased in patients with early or localized disease.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshBreast Neoplasms/blood/*metabolism/pathology/surgeryen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMucin-1/blood/chemistry/*metabolismen_GB
dc.subject.meshNeoplasm Metastasisen_GB
dc.subject.meshPostoperative Perioden_GB
dc.subject.meshPreoperative Perioden_GB
dc.subject.meshTumor Markers, Biological/blood/chemistry/*metabolismen_GB
dc.titleCA 15-3: uses and limitation as a biomarker for breast cancer.en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin 4, Ireland. Michael.J.Duffy@ucd.ieen_GB
dc.identifier.journalClinica chimica acta; international journal of clinical chemistryen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.